Champredon David, Bellan Steven E, Delva Wim, Hunt Spencer, Shi Chyun-Fung, Smieja Marek, Dushoff Jonathan
McMaster University, Hamilton, ON, Canada, Austin, TX, USA.
Center for Computational Biology and Bioinformatics, The University of Texas at Austin, Austin, TX, USA.
BMC Infect Dis. 2015 Jun 30;15:249. doi: 10.1186/s12879-015-0961-5.
Antiretroviral therapy (ART) markedly reduces HIV transmission, and testing and treatment programs have been advocated as a method for decreasing transmission at the population level. Little is known, however, about the extent to which sexually transmitted infections (STIs), which increase the HIV infectiousness of untreated individuals, may decrease the effectiveness of treatment as prevention.
We searched major bibliographic databases to August 12(th), 2014 and identified studies reporting differences in HIV transmission rate or in viral load between individuals on ART who either were or were not co-infected with another STI. We used hierarchical Bayesian models to estimate viral load differences between individuals with and without STI co-infections.
The search strategy retrieved 1630 unique citations of which 14 studies (reporting on 4607 HIV viral load measurements from 2835 unique individuals) met the inclusion criteria. We did not find any suitable studies that estimated transmission rates directly in both groups. Our meta-analysis of HIV viral load measurements among treated individuals did not find a statistically significant effect of STI co-infection; viral loads were, on average, 0.11 log10 (95% CI -0.62 to 0.83) higher among co-infected versus non-co-infected individuals.
Direct evidence about the effects of STI co-infection on transmission from individuals on ART is very limited. Available data suggests that the average effect of STI co-infection on HIV viral load in individuals on ART is less than 1 log10 difference, and thus unlikely to decrease the effectiveness of treatment as prevention. However, there is not enough data to rule out the possibility that particular STIs pose a larger threat.
抗逆转录病毒疗法(ART)可显著降低HIV传播,检测和治疗项目已被倡导作为一种在人群层面降低传播的方法。然而,关于性传播感染(STIs)在多大程度上会降低治疗即预防的效果,人们知之甚少。性传播感染会增加未治疗个体的HIV传染性。
我们检索了截至2014年8月12日的主要文献数据库,并确定了报告接受ART治疗且合并或未合并其他性传播感染的个体之间HIV传播率或病毒载量差异的研究。我们使用分层贝叶斯模型来估计合并或未合并性传播感染的个体之间的病毒载量差异。
检索策略共获得1630条独特的引文,其中14项研究(报告了来自2835名独特个体的4607次HIV病毒载量测量结果)符合纳入标准。我们没有找到任何直接估计两组传播率的合适研究。我们对接受治疗个体的HIV病毒载量测量结果进行的荟萃分析未发现性传播感染合并感染有统计学显著影响;合并感染个体的病毒载量平均比未合并感染个体高0.11 log10(95%可信区间为-0.6至0.83)。
关于性传播感染合并感染对接受ART治疗个体传播的影响的直接证据非常有限。现有数据表明,性传播感染合并感染对接受ART治疗个体的HIV病毒载量的平均影响小于1 log10差异,因此不太可能降低治疗即预防的效果。然而,没有足够的数据排除特定性传播感染构成更大威胁的可能性。